Bone marrow protection drug for advanced bile duct and pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with bile duct cancer or pancreatic cancer and are planning to have chemotherapy.
- You are generally able to do daily activities (performance status 0 or 1) and expected to live at least 3 months.
- Your blood counts, liver, kidney, and heart tests are mostly normal.
- You have not had leukemia, myelodysplastic syndrome, or sickle cell disease.
- You have no cancer spread to the brain or spinal cord causing symptoms.
- You have not had major surgery or radiation within the past 4 weeks.
- You have no significant lung scarring or inflammatory lung disease.
- You are not pregnant or breastfeeding, and you are willing to follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
This trial tests a drug called trilaciclib that may help protect your bone marrow from the side effects of a type of chemotherapy called an ADC drug. If you are scheduled to receive an ADC drug for your cancer, this study could help reduce the risk of low blood counts and the need for blood transfusions.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.